{"id":"sulpiride-use","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Drowsiness"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"1-5%","effect":"Parkinsonism"}]},"_chembl":{"chemblId":"CHEMBL26","moleculeType":"Small molecule","molecularWeight":"341.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the action of dopamine, a neurotransmitter involved in the regulation of movement and coordination. This leads to an increase in the activity of dopamine receptors, which helps to reduce symptoms of schizophrenia and other psychiatric disorders.","oneSentence":"Sulpiride is a dopamine antagonist that acts on D2 receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:44.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Treatment-resistant schizophrenia"}]},"trialDetails":[{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT02749747","phase":"PHASE3","title":"Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-06","conditions":"Menopausal Syndrome, Hot Flashes","enrollment":28},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT01896349","phase":"NA","title":"Interpersonal Psychotherapy for Treatment Resistant Depression","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2013-04","conditions":"Treatment Resistant Depression","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":448,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sulpirida"],"phase":"phase_3","status":"active","brandName":"Sulpiride use","genericName":"Sulpiride use","companyName":"Hospital de Clinicas de Porto Alegre","companyId":"hospital-de-clinicas-de-porto-alegre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sulpiride is a dopamine antagonist that acts on D2 receptors in the brain. Used for Schizophrenia, Treatment-resistant schizophrenia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}